Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Nektar Therapeutics

46.99
-13.5550-22.39%
Post-market: 47.000.0100+0.02%19:59 EDT
Volume:6.27M
Turnover:308.15M
Market Cap:1.60B
PE:-7.26
High:56.69
Open:55.41
Low:46.29
Close:60.55
52wk High:109.00
52wk Low:33.40
Shares:34.14M
Float Shares:28.53M
Volume Ratio:3.19
T/O Rate:21.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.4680
EPS(LYR):-9.7254
ROE:-35.75%
ROA:-12.54%
PB:1.78
PE(LYR):-4.83

Loading ...

OverviewCompanyNewsFilings

U.S. Stocks on the MOVEx-Microsoft, Nike, Nektar Therapeutics

Reuters
·
Sep 26

Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case

MT Newswires Live
·
Sep 26

Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG

Dow Jones
·
Sep 25

Sector Update: Healthcare Stocks Edge Higher Premarket Friday

MT Newswires Live
·
Sep 25

Jury Finds Lilly Breaches Implied Covenant in Rezpegaldesleukin License, Awards Nektar USD 90 Million Plus Interest

Reuters
·
Sep 25

Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 25

Nektar Therapeutics - Jury Awards Nektar Therapeutics $90 Mln in Damages Plus Interest - SEC Filing

THOMSON REUTERS
·
Sep 25

Nektar shares pressured by jury notes in Lilly case, says B. Riley

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)

TIPRANKS
·
Sep 23

Nektar Therapeutics is Maintained at Neutral by Wedbush

Dow Jones
·
Sep 23

Wedbush Cuts Price Target on Nektar Therapeutics to $50 From $80, Keeps Neutral Rating

MT Newswires Live
·
Sep 23

Nektar Therapeutics : Wedbush Cuts Target Price to $50 from $80

THOMSON REUTERS
·
Sep 23

Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG

Dow Jones
·
Sep 16

Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG

Dow Jones
·
Sep 09

Nektar Therapeutics - Enters Quiet Period Beginning Sept 8, 2026 Until Phase 2B Rezolve-Aa Study Data - SEC Filing

THOMSON REUTERS
·
Sep 09

Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR)

Simply Wall St.
·
Aug 31

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Reuters
·
Aug 29

Nektar Grants Inducement Equity Awards to New Hires, Including Options Priced at USD 74.53

Reuters
·
Aug 29

Nektar Therapeutics - Rezolve-Ad Study Meets All Primary and Key Secondary Endpoints for Rezpegaldesleukin 24 ΜG/Kg Q2w

THOMSON REUTERS
·
Aug 25

Nektar Therapeutics : JP Morgan Resumes Coverage with Neutral Rating; Target Price $65

THOMSON REUTERS
·
Aug 21
More